New Compass for Precision Oncology: Evidence, Challenges, and Prospects of Circulating Tumor DNA in Colorectal Cancer.

83 Although ALTAIR did not reach statistical significance for its primary endpoint, FTD/TPI demonstrated a clinically meaningful DFS benefit in the subgroup of patients with resected oligometastatic disease (FTD/TPI: 9.76 vs placebo: 3.96 months, HR: 0.53, P = 0.012), suggesting that this subset may derive particular benefit from ctDNA-guided treatment es

also in 111,027 other papers